Trogocytosis-mediated therapy using cd38 antibodies
AssigneeGenmab A/S
InventorsBart E. C. G. DE GOEIJ, Grietje ANDRINGA, Frank BEURSKENS, Janine SCHUURMAN, David SATIJN, Tahamtan AHMADI
Life of this patent
Estimating the term…
Abstract
Antibody variants for therapeutic use involving trogocytosis-mediated reduction of CD38 on CD38-expressing immunosuppressive cells; particularly CD38 antibody variants comprising one or more mutations in the Fc region, such a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino 5 acid residues are numbered according to the EU index.
Claims53
A method of treating cancer in a subject,
- the method comprising administering to the subject an effective amount of an antibody comprising an antigen-binding region which binds to CD38 and an Fc region comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index, and wherein the antibody induces trogocytosis-mediated reduction of CD38 on CD38-expressing immune cells.
(canceled)
(canceled)
-8. (canceled)
(canceled)
-13. (canceled)
-21. (canceled)
(canceled)
-29. (canceled)
-32. (canceled)
-36. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-54. (canceled)
-57. (canceled)
-60. (canceled)
A method of treating cancer in a subject, the method comprising administering an effective amount of a nucleic acid or combination of nucleic acids encoding an antibody comprising an antigen-binding region which binds to CD38 and an Fc region comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index, and wherein said antibody induces trogocytosis-mediated reduction of CD38 on CD38-expressing immune cells.
(canceled)
-67. (canceled)
A method of promoting an immune response in a subject, the method comprising administering to the subject an antibody comprising an antigen-binding region which binds to CD38 and an Fc region comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index, and wherein the antibody induces trogocytosis-mediated reduction of CD38 on CD38-expressing immune cells.
-75. (canceled)
A method of promoting an immune response in a subject, the method comprising administering an effective amount of a nucleic acid or combination of nucleic acids which encodes an antibody comprising an antigen-binding region which binds to CD38 and an Fc region comprising a mutation in one or more amino acid residues corresponding to E430, E345 and S440 in a human IgG1 heavy chain, wherein the amino acid residues are numbered according to the EU index, and wherein said antibody induces trogocytosis-mediated reduction of CD38 on CD38-expressing immune cells.
-78. (canceled)
-95. (canceled)
Dependencies are inferred from the claim text.